Inversago Pharma Inc. (Inversago), A Clinical Stage Biotech Company With A Unique Portfolio Of Peripherally-Acting Cb1 Inverse Agonists, Has Received Fda Clearance Of Its Investigational New Drug (Ind) Application For A Phase 2 Study In Diabetic Kidney Disease (Dkd) For Inv-202, The Company
